Published in Br J Haematol on October 01, 2001
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest (2007) 2.36
Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol (2003) 1.50
Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study. PLoS One (2016) 1.48
Particulate matter-induced lung inflammation increases systemic levels of PAI-1 and activates coagulation through distinct mechanisms. PLoS One (2011) 1.21
Effects of gender and dementia severity on Alzheimer's disease caregivers' sleep and biomarkers of coagulation and inflammation. Brain Behav Immun (2008) 1.03
β₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. J Clin Invest (2014) 1.00
Factor VIII in the setting of acute ischemic stroke among patients with suspected hypercoagulable state. Clin Appl Thromb Hemost (2013) 0.96
The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS (2009) 0.96
Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut (2005) 0.95
Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm (2010) 0.90
Long-term variability of inflammatory markers and associated factors in a population-based cohort. J Am Geriatr Soc (2013) 0.90
Crimean-Congo hemorrhagic fever virus activates endothelial cells. J Virol (2011) 0.89
Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol (2012) 0.87
Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS (2010) 0.87
Associations between fibrin D-dimer, markers of inflammation, incident self-reported mobility limitation, and all-cause mortality in older men. J Am Geriatr Soc (2014) 0.86
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis. Int Semin Surg Oncol (2005) 0.82
Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension. PLoS One (2013) 0.81
Fucoidan extracted from Fucus evanescens prevents endotoxin-induced damage in a mouse model of endotoxemia. Mar Drugs (2014) 0.80
Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells. Leuk Res (2013) 0.80
HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma. Am J Surg Pathol (2014) 0.80
Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study. Crit Care (2013) 0.79
Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. PLoS One (2014) 0.78
Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study. Cardiovasc Diabetol (2012) 0.78
Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von Willebrand factor and IL-6 in the peripheral and cardiac circulation. PLoS One (2014) 0.78
Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy. J Transl Med (2012) 0.78
Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. J Thromb Haemost (2016) 0.77
Sex differences in the association between stressor-evoked interleukin-6 reactivity and C-reactive protein. Brain Behav Immun (2016) 0.76
Associations between vitamin K status and haemostatic and inflammatory biomarkers in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis. Thromb Haemost (2014) 0.76
On-versus Off-Pump Coronary Artery Bypass Grafting: No Difference in Early Postoperative Kidney Function Based on TNF-α or C-Reactive Protein. Cardiorenal Med (2012) 0.75
Portopulmonary hypertension in cirrhosis: the pathogenetic challenge. Gut (2005) 0.75
Linking air pollution exposure with thrombosis. Blood (2011) 0.75
Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis. Med Sci Monit (2016) 0.75
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema. Blood Coagul Fibrinolysis (2015) 0.75
High-sensitivity C-reactive protein (hs-CRP) and tumor necrotizing factor-alpha (TNF-alpha) after on- and off- pump coronary artery bypass grafting. HSR Proc Intensive Care Cardiovasc Anesth (2010) 0.75
Tissue factor: A potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells. Int J Med Sci (2016) 0.75
The assessment of proinflammatory cytokines in the patients with the history of cerebral venous sinus thrombosis. Iran J Neurol (2016) 0.75
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res (2016) 0.75
Portal Venous Thrombosis-Disseminated Tuberculosis in Rheumatoid Arthritis. J Clin Diagn Res (2017) 0.75
Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Guidelines for the management of hemophilia. Haemophilia (2012) 5.16
Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet (1998) 5.15
Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc Natl Acad Sci U S A (1992) 3.58
Infection with hepatitis G virus among recipients of plasma products. Lancet (1996) 3.25
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ (1997) 2.83
Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. J Virol (1990) 2.68
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
The end of the heparin pump? Low molecular weight heparin has many advantages over unfractionated heparin. BMJ (1998) 2.13
Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet (1985) 2.08
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet (1990) 2.01
New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation. Lancet (1997) 1.94
Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS (1991) 1.93
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet (2008) 1.90
Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J (2001) 1.87
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Acquired haemophilia and its management. Br J Haematol (1995) 1.69
Treatment for haemophilia by postcode. BMJ (1997) 1.67
Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet (1991) 1.58
Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart (2009) 1.54
Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood (1993) 1.46
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost (1997) 1.45
Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ (1998) 1.44
Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms. J Vasc Surg (1999) 1.44
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet (1988) 1.41
Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells--the importance of consensus on the use of correction factors for haemoconcentration. Thromb Haemost (1993) 1.40
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation (1999) 1.40
Management of acquired von Willebrand's syndrome in a patient requiring major surgery. Haemophilia (2005) 1.40
Confirmation of non-infection in persistently HIV-seronegative recipients of contaminated factor VIII. Lancet (1990) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res (1975) 1.31
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol (2002) 1.30
TT virus--part of the normal human flora? J Infect Dis (1999) 1.29
HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort. Br Med J (Clin Res Ed) (1988) 1.27
Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med (1996) 1.24
Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis (1994) 1.23
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol (1998) 1.20
Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia (2007) 1.13
Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost (2001) 1.12
Studies on liberation of beta-thromboglobulin from human platelets in vitro. Br J Haematol (1976) 1.10
Pectenotoxin-2 seco acid: a toxin converted from pectenotoxin-2 by the New Zealand Greenshell mussel, Perna canaliculus. Toxicon (2001) 1.10
Discrimination of hepatitis G virus/GBV-C geographical variants by analysis of the 5' non-coding region. J Gen Virol (1997) 1.09
Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.07
Audit of oral anticoagulant treatment. The BCSH Haemostasis and Thrombosis Task Force of the British Society for Haematology. J Clin Pathol (1993) 1.06
Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther (2001) 1.02
Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J (1992) 1.02
EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res (2011) 1.02
Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol (1992) 1.02
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart (2005) 1.01
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer (2005) 1.01
A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb Haemost (1984) 1.01
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Three approaches to the radioimmunoassay of human beta-thromboglobulin. Br J Haematol (1976) 0.99
Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses (1997) 0.99
Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. BMJ (1990) 0.99
Bone mineralization and turnover in preterm infants at 8-12 years of age: the effect of early diet. J Bone Miner Res (1999) 0.98
HTLV-III infection associated with glandular-fever-like illness in a haemophiliac. Lancet (1985) 0.98
The procoagulant potential of environmental particles (PM10). Occup Environ Med (2005) 0.98
New rapid method for diagnosis of deep venous thrombosis. Lancet (1975) 0.97
Antenatal diagnosis. Baillieres Clin Haematol (1991) 0.96
A radioimmunoassay for platelet factor 4. Thromb Res (1976) 0.95
cDNA sequence, deduced amino acid sequence, predicted gene structure and chemical regulation of mouse Cyp2e1. Biochem J (1992) 0.93
Emotional impact of diagnosis and early treatment of lymphomas. J Psychosom Res (1984) 0.92
Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost (2008) 0.92
Effects of acute liver injury on blood coagulation. J Thromb Haemost (2003) 0.92
An HIV positive haemophiliac with acute lymphoblastic leukaemia successfully treated with intensive chemotherapy and syngeneic bone marrow transplantation. Bone Marrow Transplant (1992) 0.92
The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group. Semin Hematol (1993) 0.91
Immunological, histological and biochemical assessment of brown adipose tissue activity in neonatal, control and beta-stimulant-treated adult dogs. Int J Obes (1987) 0.91
Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. Blood (1995) 0.90
Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair. Ann Vasc Surg (2004) 0.89
Abnormalities of circulating lymphocyte subsets in haemophiliacs in an AIDS-free population. Lancet (1984) 0.89
Prothrombin time to assess fulminant hepatic failure. Lancet (2002) 0.89
Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood (1996) 0.89
Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses (2000) 0.89
Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabet Med (2000) 0.89
Evidence for the platelet specificity of beta-thromboglobulin and studies on its plasma concentration in healthy individuals. Br J Haematol (1979) 0.88
Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. Am J Hematol (1995) 0.88
Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response. Blood (1996) 0.88
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol (1994) 0.87
Biovigilance and pharmacovigilance for haemophilia. Haemophilia (2010) 0.87
European curriculum for thrombosis and haemostasis. Haemophilia (2009) 0.86
The coagulative and cardiorespiratory responses to reamed intramedullary nailing of isolated fractures. J Bone Joint Surg Br (2001) 0.86
Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A. Haemophilia (2000) 0.86
Human parvovirus B19 and blood products. Vox Sang (1997) 0.85
Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost (1998) 0.84
Plasminogen assay by a haemagglutination inhibition technique. J Clin Pathol (1971) 0.84
Haematological indices in elderly patients with epistaxis. Health Bull (Edinb) (1988) 0.84
Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease. Br J Haematol (1980) 0.83
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia (2009) 0.83
An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand's disease and fetal plasma and serum. Br J Haematol (1979) 0.83
Does avascular necrosis cause collapse of the dome of the talus in severe haemophilia? Haemophilia (1999) 0.82
Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods. Br J Haematol (1996) 0.82
Carrier detection in haemophilia a by immunological measurement of factor VIII related antigen (VIIIRAg) and factor VIII clotting antigen (VIIICAg). Br J Haematol (1981) 0.82